Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement.
June 22, 2022
· 3 min read